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Objective: Nanotechnology has been identified as a promising platform in the improvement 
of the design and development of drug delivery systems. In the present study we investi-
gated the potential of lipidic nanoparticles consisting of gold porphyrin for the treatment of 
neuroblastoma.
Materials and methods: To characterize the size of the lipidic gold porphyrin nanoparticles, 
we used transmission electron microscopy (TEM). The in vitro cytotoxic effect on neuroblastoma 
activity was examined using XTT cell proliferation assay, then IC
50
 values were calculated. In vivo 
safety and toxicity were studied using intraperitoneal injection of gold porphyrin nanoparticles into 
normal animals. Finally, tumor size measurement and animal survival were studied to investigate 
the therapeutic effect of lipidic gold porphyrin nanoparticles on neuroblastoma growth.
Results: We found that incorporation of gold porphyrin into lipidic nanoparticles resulted in a 
16-fold increase in size. Subsequent in vitro and in vivo cytotoxicity studies further showed that 
the lipidic gold porphyrin nanoparticles could decrease systemic toxicity, as well as inhibiting 
tumor growth following administration into the neuroblastoma bearing mice.
Conclusion: The delivery of lipidic gold porphyrin nanoparticles by incorporation with lipidic 
formulation is feasible approach to treat neuroblastoma. We await further studies to evaluate 
tumor killing kinetics.
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A delivery system that is capable of reducing toxicity improves the design in 
 formulation of cancer therapeutics. This is especially true when treatment is required 
for long term administration, for example in neuroblastoma, which is a cancer of the 
sympathetic nervous system. It is the most common solid tumor in children, making 
up approximately 7% of all childhood tumors.1 Despite advances in medical technol-
ogy, the overall tumor-related survival rate across all stages is still only around 50%. 
Furthermore, because of minimal symptoms at the early stages, many neuroblastoma 
cases are diagnosed after the cancer has metastasized to other parts of the body. Thus, 
a common treatment option for neuroblastoma is high dosages of chemotherapy and/
or radiotherapy.2 However common chemotherapeutics for treating neuroblastoma, 
such as cisplatin, can cause significant systemic side effects.3
Neuroblastoma is known to have a disorganized vascular network.4 Despite the 
presence of leaky blood vessels supplying the tumor, clearance can be slow due to slow 
lymphatic drainage.5,6 Macromoleculer therapeutics, such as nanoparticles, therefore 
tend to accumulate in the tumor. The concept of enhanced permeability and retention 
(EPR) is the standard for the development and design of lipidic, micellar, or polymeric 
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anticancer therapeutics. Results of preclinical studies have 
found that the nanoparticle based delivery system shows 
promise as a selective tumor targeting strategy by utilizing 
the abnormal anatomical structure in the tumor.7–9
The recently developed gold(III) porphyrin complex 
(gold-1a) forms a new generation in gold(III)-based cancer 
chemotherapeutics.10,11 Unlike the first generation anticancer 
gold compounds, which are unstable in physiological condi-
tions, the tetradentate porphyrinato ligand of gold-1a stabilizes 
the gold(III) ion against reduction and demetalation.12 In vitro 
and preclinical studies have demonstrated its potency against a 
wide range of cancers such as nasopharyngeal carcinoma and 
hepatocellular carcinoma.13 It was recently reported that gold 
porphyrin is a potent inhibitor of thioredxin reductase that is 
responsible for regulating the overall intracellular reduction/
oxidation balance.14 It can be a more potent antitumor agent 
than currently available chemotherapeutic agent, cisplatin, 
with a maximum at 100 fold higher cytotoxicity.13 It has 
also been suggested that the possible apoptotic  mechanism 
of c ancerous cells might involve the caspase-signaling 
 pathway.15 Gold(III) porphyrin also greatly affects the func-
tion of mitochondria and results in cell apoptosis.16
As has been demonstrated in most traditional chemo-
therapeutics, undesirable side effects in nontumoral tissue are 
often due to the high toxicity contained in these treatments. 
The present study was aimed at exploring the feasibility of 
a nanotechnology-based approach for the delivery of gold 
 porphyrin. We designed lipidic gold porphyrin nanopar-
ticles by incorporating the free gold porphyrin into a lipidic 
 formulated carrier and evaluated the in vitro and in vivo 
toxicity. The lipidic based nanoparticle carriers were made 
of cetyl alcohol and the resulting nanoparticle was deter-
mined to be safe and biocompatible with the great blood 
compatibility based on the report by Mumper et al.17 To 
prolong the circulation duration in the in vivo system, we 
further incorporated poly(ethylene) glycol (PEG) into the 
nanoparticles as previously described.18 In order to evaluate 
the in vivo efficacy of lipidic gold porphyrin nanoparticles, 
we examined the antitumor activity in the A/J neuroblastoma 
mouse model.
Materials and methods
Neuroblastoma cell lines
Five human neuroblastoma cell lines LAN-1, LAN-2 (ICLC, 
Genova, Italy), SH-SY5Y, Be(2)-C, CHP-212 (ATCC, 
Manassas, VA) were cultured in MEM and a mouse neuro-
blastoma cell line N2A (ATCC, Manassas, VA) was cultured 
in DMEM according to the manufacture protocol.
Synthesis of lipidic gold porphyrin 
nanoparticles
Gold(III) porphyrin complex (gold-1a) was kindly provided 
by the Department of Chemistry, HKU. The lipidic gold por-
phyrin nanoparticles were prepared as previously described 
using oil in water (o/w) microemulsion.19 Briefly, 1 mL of 
lipidic gold porphyrin nanoparticles was synthesized by 
completely dissolving the gold porphyrin in the oil phase of 
cetyl alcohol at 60°C. Surfactant Brij 78 was added to the oil 
phase and stirred for 5 minutes. To form the microemulsion 
template, 1 mL of deionized water was added and stirred well 
for 20 minutes. The microemulsion template was cooled at 
room temperature for 10 minutes to form lipidic gold por-
phyrin nanoparticles. The size of lipidic gold porphyrin 
nanoparticles was characterized using transmission electron 
microscopy (TEM). Briefly, the specimen on the supporting 
copper grid was prepared by dipping into free gold porphyrin 
nanoparticles in ethanol or lipidic gold porphyrin nanopar-
ticles in water solution. The samples were dried on a copper 
wire and placed in a vacuum chamber for imaging.
In vitro cytotoxicity assay
The six neuroblastoma cell lines LAN-1, LAN-2, SH-SY5Y, 
Be(2)-C, CHP-212, and N2A were seeded in a 96 well plate 
and incubated with free gold porphyrin nanoparticles or 
lipidic gold porphyrin nanoparticles for 6 hours. Following 
incubation, the XTT (Sodium 3,3’-(-[(Phenlamino)carbonyl]-
3,4-tetrazolium)-bis(4-methoxyl-6-nitro)benzene sulfonic 
acid hydrate) colorimetric assay was performed according to 
the manufacturer’s protocol (Roche Diagnostics, Indianapo-
lis, IN) and IC
50
 values, measured as the concentration of drug 
required to inhibit 50% of the cell growth, were calculated by 
constructing a dose dependent curve.13 XTT is a quantitative 
colorimetric assay based on the development of an orange 
formazan dye by viable cells from the cleavage of the yellow 
XTT tetrazolium salts. Briefly, 104 of individual cells were 
seeded in each well of a 96 well plate and cultured at 37°C 
in a 5% CO
2
 incubator. A negative control using the cell 
culture medium only was taken as the blank. XTT assay was 
performed using the ELISA plate reader with absorbance at 
480 nm and the reference absorbance at 650 nm as the filter 
according to the protocol provided from the commercial kit 
(Roche Diagnostic, Indianapolis, IN).
In vivo efficacy of anticancer activity  
in the neuroblastoma model
Six to eight week old male inbred A/J albino mouse strain 
widely used in immunology and cancer study, weighing 
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20 ± 2 g were obtained from and housed in the Laboratory 
Animal Unit at The University of Hong Kong. Experimen-
tation protocol was approved by the Committee on the Use 
of Live Animals for Teaching and Research, University of 
Hong Kong (CULATR case no. 1901-09). A 200 µl mouse 
neuroblastoma cell line (N2A) with the density of 1.5 × 106/ml 
resuspended in PBS was subcutaneously inoculated on the 
right flank of A/J mouse. At 11 days after inoculation, mice 
were either untreated or treated with intraperitoneal injection 
of 0.08 mg or 0.1 mg (approximately 4 or 5 mg/kg of mouse) 
of lipidic gold porphyrin nanoparticles every 7 days (n = 6). 
Measurement of tumor volume was conducted every 3 days for 
a total of 21 days. For the survival rate study, the lipidic gold 
porphyrin nanoparticles at 0, 0.04, 0.06, 0.08, 0.1, and 0.3 mg 
(approximately 0, 2, 3, 4, 5, 15 mg/kg of mouse) or free gold 
porphyrin nanoparticles at 0.1 mg (approximately 5 mg/kg of 
mouse) was intraperitoneally injected into the mouse.
Statistical analysis
Data was analyzed using the parametric Student’s t test and 
P , 0.05 was taken the level of statistical significance.
Results
Size determination of gold porphyrin 
nanoparticles
TEM was used to determine the average size of free gold 
porphyrin nanoparticles and lipidic gold porphyrin nano-
particles. The average diameter of free gold porphyrin 
nanoparticles was approximately 2–5 nm and of lipidic gold 
porphyrin nanoparticles was approximately 80 ± 30 nm. 
This indicates that incorporation of lipid coating resulted in 
a 16-fold increase in size (Figure 1).
In vitro toxicity
An XTT assay was conducted to evaluate the in vitro anti-
tumor activity of free gold porphyrin nanoparticles and  lipidic 
gold porphyrin nanoparticles. Both free gold  porphyrin 
nanoparticles and lipidic gold porphyrin nanoparticles 
 demonstrated positive cytotoxicity against all six neuroblas-
toma cell lines: N2A, CHP-212, Be(2)-C, SH-SY5Y, LAN-1, 
and LAN-2. The IC
50
 values showed that the cytotoxicity 
of both lipidic gold porphyrin nanoparticles and free gold 
porphyrin nanoparticles against the six neuroblastoma cell 
lines was dose dependent (data not shown). The IC
50
 value 
determined by the dose dependent curve of lipidic gold por-
phyrin nanoparticles was higher in N2A, CHP-212, Be(2)-C, 
SH-SY5Y, while it was lower in LAN-1 and LAN-2 when 
compared with free gold porphyrin nanoparticles (Table 1). 
This would suggest that various cell lines had different 
 sensitivity to the lipidic gold porphyrin nanoparticles.
In vivo cytotoxicity
For the design of a nanoparticle with a long half-life in 
the systemic circulation in vivo, PEG was used to coat the 
 nanoparticles. The 28 day survival study showed that 100% 
of the mice survived after receiving intraperitoneal  injection of 
0.02, 0.04, 0.06, 0.08, 0.1, or 0.3 mg of lipidic gold  porphyrin 
nanoparticles (Figure 2). In contrast, the  survival rate dropped 
to 50% at day 6 after 0.1 mg of free gold  porphyrin nanopar-
ticles was administered. This indicated the lipidic nanoparticle 
formulation reduced the toxicity of the free gold porphyrin 
nanoparticles.
In vivo activity against neuroblastoma
Subsequent study of in vivo antitumor kinetics was  carried 
out. Tumor volume measurement was performed to 
investigate the in vivo efficacy of lipidic gold porphyrin 
 nanoparticles. Tumor volume measurement was determined 
with the untreated and treated mice with increasing doses 
of lipidic gold porphyrin nanoparticles. Treatment of mice 
with 0.08 mg or 0.1 mg of lipidic gold porphyrin nanopar-
ticles  demonstrated a reduction of neuroblastoma growth 
compared with the untreated control (Figure 3a). Tumor size 
Figure 1 Size characterization by transmission electron microscopy (TeM) of 
A) free gold porphyrin, or B) lipidic gold porphyrin nanoparticles. The scale bar 
represents 20 nm or 0.5 µm.
Table 1 ic50 values of 6 neuroblastoma cell lines N2A, chP-212, 
Be(2)-c, Sh-SY5Y, LAN-1, and LAN-2 treated with either free 
gold porphyrin nanoparticles (Free gP) or lipidic gold porphyrin 
nanoparticles (Lipidic gPNP)
Cell lines Lipidic GPNP mg/ml Free GP mg/ml
N2A 0.013 0.0032
chP-212 0.0075 0.0007
Be(2)-c 0.003 0.0006
Sh-SY5Y 0.003 0.0012
LAN-1 0.0037 0.0076
LAN-2 0.0034 0.0067
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 following treatment with the 0.1 mg or 0.08 mg of lipidic gold 
 porphyrin nanoparticles per week were approximately 14% 
(one-seventh) of the untreated tumor size (Figure 3a).
Furthermore, at the therapeutic doses of 0.08 mg and 
0.1 mg lipidic gold porphyrin nanoparticles, tumor bearing 
mice survived up to 21 days at which time the animals were 
 sacrificed. On the other hand, mice treated with 0.1 mg of free 
gold  porphyrin nanoparticles survived only 2 days (Figure 3b). 
This would suggest that the nanoparticle  carrier was able to 
reduce the inherent toxicity of the free gold porphyrin nano-
particles. Nonetheless, at a higher dose of 0.1 mg, lipidic gold 
porphyrin nanoparticles still exhibited systemic toxicity. For the 
untreated mice, only 66% survived at day 21, potentially due to 
the advanced and disseminated neuroblastoma (Figure 3b).
Discussion
Nanotechnology has received much attention in relation 
to drug delivery. Recent advances in the design of drug 
delivery system for cancer therapeutics have indicated 
platforms such as polymer micelles, lipidic carriers, and 
nanoparticles facilitate drug delivery with minimal toxic-
ity. Traditional administration of free cancer therapeutics 
to neuroblastoma usually produces side effects. Long term 
and high dosage administration are required and this often 
causes accumulation in the kidneys and liver, which can 
cause irreversible damage to these organs and can therefore 
be life threatening.
To reduce toxicity, various strategies are required to facil-
itate the delivery of cancer therapeutics into the tumors. In the 
presence of the EPR effect, nanotechnology can be beneficial 
by coupling macromolecular carriers with small-size drugs. 
We found that the incorporation of lipidic carrier increases 
the neuroblastoma size 10 fold, with an average diameter 
of approximately 80 ± 30 nm (Figure 1). The increase in 
size can be favorable for drug accumulation in the tumor 
tissue based on EPR effect, as well as the slower lymphatic 
drainage. Through the size independent transfer from the 
peritoneal to bloodstream, nanoparticles can reach the tumor 
via the blood circulation.20 Unlike small drugs which can be 
removed rapidly by the lymphatic system,  macromolecules 
are too large to enter. In this case, the peritoneal cavity can 
serve as a drug depot for supporting the transfer to blood-
stream. In fact, a significant increase in accumulation of large 
drugs was reported in the peritoneal cavity following the 
intraperitoneal route.21 In the normal vessel with a pore size 
of approximately 6 nm (17), the 80 ± 30 nm nanoparticles 
cannot pass through the endothelial membrane. However, the 
pore of tumor vasculature could be as large as 400 nm and 
allow for the diffusion of the macromolecules into the tumor 
tissue.22 Due to the increased permeability of endothelial 
barrier in tumor vasculature, our delivery carrier is feasible 
for use in various administration routes via blood circulation, 
such as intravenously.
The importance of free gold porphyrin nanoparticles 
against neuroblastoma has been shown in previous reports 
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of in vitro and preclinical studies.23 Consistent with previous 
findings, our data show that the free gold porphyrin nano-
particles are able to kill neuroblastoma cells. Our in vitro 
cytotoxicity examination demonstrated the effective killing 
of neuroblastoma cells using the carrier system. Interestingly, 
the IC
50
 value of lipidic gold porphyrin nanoparticles was 
much higher than free gold porphyrin nanoparticles. This 
may be due to the gold porphyrin being sequestered inside 
the nanoparticle carrier and needing time to be released. The 
different release kinetics of free gold porphyrin nanoparticles 
and lipidic gold porphyrin nanoparticles have been evidenced 
in a previous report involving liposome encapsulated drugs.24 
Consistent with the in vitro cytotoxicity study, the intrap-
eritoneal injection of lipidic gold porphyrin nanoparticles 
demonstrated an inhibition of the neuroblastoma growth 
(Figure 3). A possible explanation of the bioavailability 
inside the neuroblastoma tissue, despite the EPR effect, 
could be the chemical property of the nanoparticle carrier. 
The carrier consists of a fatty acid alcohol, cetyl alcohol. The 
incorporation of fatty acid alcohol into the lipid bilayer of the 
cell membrane occurs by lipid-lipid interaction.25 Results of 
the present study shed light on the mechanism of intracellular 
trafficking and internalization of lipidic carriers.
We observed different cytotoxicity in the six different 
neuroblastoma cell lines; this could be due to the different cell 
sensitivity to the gold porphryin. Since higher cytotoxicity of 
lipidic gold porphyrin nanoparticles was found in the LAN 
cell lines, it is possible that LAN is more sensitive to the 
lipidic gold porphryin nanoparticles, which would mean that 
it induced greater apoptosis. The different induction of apop-
tosis among the human neuroblastoma cell lines in response 
to drug was also evidenced in previous in vitro study.26
The potential benefits in clinical application can be revealed 
by ruling out the toxicity associated in a biological system. 
The A/J mouse strain is a common model for neuroblastoma 
study.27,28 However, the A/J mouse strain appears to show 
higher susceptibility to gold porphyrin compared with other 
strains such as BALB/c 29 or C57Bl/6 (unpublished data). This 
was seen in our in vivo study that all the A/J mice died 2 days 
after administration of free gold porphyrin nanoparticles. 
By incorporation of lipidic carrier, A/J mice survived even 
after three repeated dosage administrations of gold porphyrin 
(Figure 2). As chemotherapeutics or radiotherapeutics often 
require repeated administrations, this delivery carrier can be 
beneficial in the cancer treatment by reducing the side effects. 
Further in vivo study is thus warranted.
Despite the reduced toxicity by the lipidic nanoparticle 
carrier, improvement in the design is necessary to increase 
the potency in clinical applications. The survival study 
of the neuroblastoma bearing mice showed that 100% of 
mice survived a dose of 0.08 mg of lipidic gold porphyrin 
nanoparticles, but the survival rate dropped to 33% for a 
dose of 0.1 mg gold porphyrin nanoparticles by the time 
21 days had elapsed. Thus toxicity could still be present if 
high therapeutic doses of the drug are necessary for treat-
ment. One strategy is the attachment of the specific tumor 
targeting ligand to the surface of current lipidic nanopar-
ticle carrier. This active tumor targeting strategy has been 
shown to be useful in delivery of cancer therapeutics by 
further facilitating the accumulation and cellular uptake 
inside tumors.30
In conclusion, gold porphyrin incorporated with a nano-
particle lipidic carrier demonstrated an antitumor activity 
with reduced toxicity. We therefore conclude that this is 
a useful strategy in developing a safe delivery system for 
cancer chemotherapeutics.
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